Search Results for: %D0%9A%D0%B0%D0%BA%D0%BE%D0%B3%D0%BE %D0%B6%D0%B8%D0%B2%D0%BE%D1%82%D0%BD%D0%BE%D0%B3%D0%BE 2023 %D0%B3%D0%BE%D0%B4 %D0%B1%D0%BE%D0%BB%D1%8C%D1%88%D0%B5 %D0%B2 insta---batmanapollo – Page 5

Encouraging Signs that the Insulin Affordability Battle is Improving This week, as congressional hearings focus on access to affordable insulins, it should be recognized that a multitude of market forces are working to reduce the cost of insulin products for

Legislation Would Limit Options for Employers to Provide Quality Prescription Drug Coverage for Employees The U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee is weighing several proposed policies related to the prescription drug market, including S. 1339, the Pharmacy

Speakers Discuss Pharmacy Benefit Company Innovations, Importance of Protecting Cost Saving Role, and Solutions to Improve Affordability

For millions of Americans, the prescription drug delivery system works: people, for the most part, can access the medications they need when they need them, and at the cost they expect and can afford. But “millions of Americans” does not

New Paper Finds Potential Cost Savings from Adalimumab Biosimilars are Significant but Competitive Market Will Take Time The Pharmaceutical Care Management Association (PCMA) agrees that biosimilars bring more competition to the prescription drug marketplace, which is critical to lowering costs

Casey Mulligan, Ph.D., professor of economics at the University of Chicago, member of the National Bureau of Economic Research (NBER), and former Chief Economist of the White House Council of Economic Advisers, testified before the U.S. Senate Committee on Commerce, Science, and Transportation during a hearing Thursday on S. 127.